The use of inhaled prostaglandins in patients with ARDS: A systematic review and meta-analysis

Chest

Volumn 147, Issue 6, 2015, Pages 1510-1522

  Fuller, Brian M ^a   Mohr, Nicholas M ^b   Skrupky, Lee ^c   Fowler, Susan ^a   Kollef, Marin H ^a   Carpenter, Christopher R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Aurora Baycare Medical Center Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; OXYGEN; PROSTAGLANDIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OXYGEN SATURATION; OXYGENATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOPHYSIOLOGY; PULMONARY ARTERY; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; HUMANS; LUNG; OXYGEN; PROSTAGLANDINS; PULMONARY ARTERY; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 84930890674     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-3161     Document Type: Article

References (71)

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685-1693.
2. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med. 1977;296(9):476-480.
3. Jardin F, Gueret P, Dubourg O, Farcot JC, Margairaz A, Bourdarias JP. Two-dimensional echocardiographic evaluation of right ventricular size and contractility in acute respiratory failure. Crit Care Med. 1985;13(11):952-956.
4. Squara P, Dhainaut J-F, Artigas A, Carlet J. Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study. Intensive Care Med. 1998;24(10):1018-1028.
5. Sloane PJ, Gee MH, Gottlieb JE, et al. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am Rev Respir Dis. 1992;146(2):419-426.
6. Rachmale S, Li G, Ahmed A, et al. Use of rescue therapies for ARDS patients: population-based study in Olmstead County, Minnesota. Crit Care Med. 2010;38(suppl 12):377.
7. Rachmale S, Ding S, Wilson G, Li G, Franco PM. Rescue therapies in patients with refractory hypoxemia. Am J Respir Crit Care Med. 2011;183:A1643.
8. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007;334(7597):779.
9. Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. Crit Care Med. 2014;42(2):404-412.
10. Puri N, Dellinger RP. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin. 2011;27(3):561-587.
11. Riva CM, Morganroth ML, Ljungman AG, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol. 1990;3(4):301-309.
12. Rose F, Hattar K, Gakisch S, et al. Increased neutrophil mediator release in patients with pulmonary hypertension - suppression by inhaled iloprost. Thromb Haemost. 2003;90(6):1141-1149.
13. Burghuber OC, Silberbauer K, Haber P, Sinzinger H, Elliott M, Leithner C. Pulmonary and antiaggregatory effects of prostacyclin after inhalation and intravenous infusion. Respiration. 1984;45(4):450-454.
14. Fantone JC, Marasco WA, Elgas LJ, Ward PA. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol. 1984;115(1):9-16.
15. Fantone JC, Kinnes DA. Prostaglandin E1 and prostaglandin I2 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun. 1983;113(2):506-512.
16. Davies A, Jones D, Bailey M, et al; Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888-1895.
17. Afshari A, Brok J, Moller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2010;(8):CD007733.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
20. Reeves B, Deeks JJ, Higgins JPT, Wells GA, on behalf of the Cochrane Non-Randomised Studies Methods Group. Including non-randomised studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. London, England: The Cochrane Collaboration; 2008.
21. Higgins J, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. London, England: The Cochrane Collaboration; 2008.
22. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.
23. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2008. Ottawa Hospital Research Institute website. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed July 17, 2014.
24. Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London, England: BMJ Publishing Group; 2001.
25. Armstrong R, Hall BJ, Doyle J, Waters E. Cochrane Update. 'Scoping the scope'of a cochrane review. J Public Health (Oxf). 2011;33(1):147-150.
26. Meyer J, Theilmeier G, Van Aken H, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg. 1998;86(4):753-758.
27. Pacheco J, Arnold H, Skrupky L, Watts P, Micek ST, Kollef MH. Predictors of outcome in 216 subjects with ARDS treated with inhaled epoprostenol. Respir Care. 2014;59(8):1178-1185.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
30. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49(5):1-15.
31. Allan PF, Codispoti CA, Womble SG, et al. Inhaled prostacyclin in combination with high-frequency percussive ventilation. J Burn Care Res. 2010;31(2):347-352.
32. Bein T, Pfeifer M, Riegger GA, Taeger K. Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure. N Engl J Med. 1994;331(5):335-336.
33. Camamo JM, McCoy RH, Erstad BL. Retrospective evaluation of inhaled prostaglandins in patients with acute respiratory distress syndrome. Pharmacotherapy. 2005;25(2):184-190.
34. Dahlem P, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med. 2004;32(4):1055-1060.
35. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med. 2001;29(1):57-62.
36. Dunkley KA, Louzon PR, Lee J, Vu S. Efficacy, safety, and medication errors associated with the use of inhaled epoprostenol for adults with acute respiratory distress syndrome: a pilot study. Ann Pharmacother. 2013;47(6):790-796.
37. McMillen JC, Burke CF, Dhingra A, Dudney TM, Faircloth BE. Use of inhaled epoprostenol in patients with H1N1 influenza-associated acute respiratory distress syndrome: a case series. Ann Pharmacother. 2011;45(5):e26.
38. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology. 1995;82(6):1507-1511.
39. Putensen C, Hörmann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157(6 pt 1):1743-1747.
40. Raheem S, Dzierba A. Aerosolized epoprostenol as adjunct therapy for acute respiratory distress syndrome. Crit Care Med. 2009;37(12):A195.
41. Ross B, Miller M, Oliveira P. A retrospective comparison of an inhaled epoprostenol dosing protocol versus conventional therapy with inhaled nitric oxide on outcomes in patients with severe acute respiratory distress syndrome. Crit Care Med. 2012;40(12 suppl 1):418.
42. Rovira I, Fabregas N, Martinez J, Alcon A, Adalia R, Zavala E. Use of selective pulmonary vasodilator therapy in a surgical ICU: analysis of 10 years. Intensive Care Med. 2004;30(suppl 1):S206.
43. Siddiqui S, Salahuddin N, Zubair S, et al. Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS - a randomised clinical trial. Open J Anesthesiol. 2013;3:109.
44. Singh A, Girdhar A, Treger K, et al. Impact of inhaled epoprostenol on oxygenation in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014;189:A3087.
45. Siobal MS, Kallet RH, Pittet J-F, et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care. 2003;48(8):742-753.
46. Torbic H, Szumita PM, Anger KE, Nuccio P, LaGambina S, Weinhouse G. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28(5):844-848.
47. van Heerden PV. Systemic levels of 6-keto-prostaglandin F1 alpha following administration of inhaled aerosolized prostacyclin. Anaesth Intensive Care. 1997;25(6):701-703.
48. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS - a pilot study. Anaesth Intensive Care. 1996;24(5):564-568.
49. Van Heerden PV, Webb SA, Hee G, Corkeron M, Thompson WR. Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia. Anaesth Intensive Care. 1996;24(1):87-90.
50. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest. 2000;117(3):819-827.
51. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 1993;342(8877):961-962.
52. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153(3):991-996.
53. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6 pt 1):1671-1677.
54. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
55. Peter M, Jaffe B, Gilbert C, Baram M. Effect of inhaled epoprostenol on oxygenation, outcome, and diuresis in critically ill patients [abstract]. Chest. 2011;140(4-MeetingAbstracts):287A.
56. Tonelli A, Sasidhar M, Heresi-Davila G, Mullin R, Conci D. Oxygenation change in patients with severe hypoxia, shunt and rescue inhaled epoprostenol. Am J Respir Crit Care Med. 2013;187:A4475.
57. McMillen J, Krumenacker L, Faircloth B, Rowe A. Effect of low dose corticosteroids on response to inhaled epoprostenol in patients with septic shock and ARDs. Crit Care Med. 2012;40(12):102.
58. Scoville BA, Tan P, Johnson DW, Aaronson P. Comparison of short-term pulmonary improvement associated with inhaled nitric oxide and inhaled epoprostenol for acute respiratory distress syndrome. Pharmacotherapy. 2011;31(10):324e.
59. Mullin R, Lam S, Conci D, Heresi G, Sasidhar M. Inhaled aerosolized prostacyclin as an efficacious and economic alternative to inhaled nitric oxide. Chest. 2012;142(4-MeetingAbstracts):401A.
60. Tabrizi MB, Schinco MA, Tepas JJ III, Hwang J, Spiwak E, Kerwin AJ. Inhaled epoprostenol improves oxygenation in severe hypoxemia. J Trauma Acute Care Surg. 2012;73(2):503-506.
61. Manickavel S, Mathew J, Africano J, Khan M, Aboeed A. Comparison Of Inhaled Nitric Oxide With Epoprostenol In Hypoxic Respiratory Failure. Am J Respir Crit Care Med. 2014;189:A4473.
62. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058-1067.
63. Dahlem P, van Aalderen WM, Bos AP. Pediatric acute lung injury. Paediatr Respir Rev. 2007;8(4):348-362.
64. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD. Incidence and outcomes of pediatric acute lung injury. Pediatrics. 2009;124(1):87-95.
65. Taylor RW, Zimmerman JL, Dellinger RP, et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291(13):1603-1609.
66. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.
67. Dellinger RP, Zimmerman JL, Taylor RW, et al; Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med. 1998;26(1):15-23.
68. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA. 1993;269(21):2749-2753.
69. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev. 2007;2(2):MR000010.
70. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 pt 1):818-824.
71. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526-2533.